Moving Beyond the Hazard Ratio to Personalized Therapy: Is it Prime Time?

In this issue of the Red Journal, there is an opinion-forming plea for the integration of genomic data into everyday counseling for patients with prostate cancer. The article “Absolute versus relative benefits of Androgen-Deprivation Therapy for Prostate Cancer: Moving beyond the Hazard Ratio to Personalized Therapy” suggests that it is prime time for integrating these tests because they are currently broadly available. However, to date, although scientific evaluatio n has continuously been promoted, it is currently not completed.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: Clinical Investigation Source Type: research